Solmaz Serife, Kahraman Selda, Sevindik Omur Gokmen, Acar Celal, Turkyilmaz Munire, Alacacioglu Inci, Piskin Ozden, Ozcan Mehmet Ali, Ozsan Hayri Guner, Undar Bulent, Demirkan Fatih
Department of Hematology, Bozyaka Teaching and Research Hospital, Izmir, Turkey.
Department of Hematology, Medical Park Hospital, Izmir, Turkey.
Indian J Hematol Blood Transfus. 2018 Oct;34(4):677-683. doi: 10.1007/s12288-018-0922-4. Epub 2018 Jan 23.
Peripheral blood is the prefered source for hematopoietic stem cells for hematopoietic stem cell transplantation. The efficiency of peripheral blood stem cell (PBSC) collection can vary among devices. In this study we aimed to compare feasibility and effectivity of apheresis procedures of the different systems. Two apheresis systems [Com.Tec (Fresenius Healthcare) and Spectra Optia (Caridian BCT)] were used in our center for the collection of PBSCs for autologous and allogeneic transplantation. We retrospectively analysed 190 apheresis procedures performed in healthy donors and patients between June 2012 and November 2014 in Department of Hematology, Dokuz Eylul University. PBSCS were collected by Fresenius cell separator (64 procedure) or Spectra Optia cell separator (126 procedure). Mobilization treatments were G-CSF (26.8%), cyclophosphamide plus G-CSF (48.4%), prelixafor plus G-CSF (14.7%), ESHAP (10%) and others. Patient and donor characteristics (age, weight, volume processed, disease, mobilization regimes) were similar in Fresenius and Spectra Optia apheresis groups. Altough both collected PBSCs efficiently, the amount of CD34+ cell in product collected by Spectra Optia device was significantly higher ( < 0.05) and product volume was lower than Fresenius Com.Tec significantly ( < 0.05). "CD34+ collection efficiency" with Spectra Optia was significantly higher than Fresenius Com.Tec (CE2: 87%, 70%, = 0.033) regarding all procedures. High collection efficiency and low product volume may be a significant characteristic of Spectra Optia device (mean 187 mL, product CD34+ cell: 1576 µL).
外周血是造血干细胞移植中造血干细胞的首选来源。外周血干细胞（PBSC）采集设备的效率可能各不相同。在本研究中，我们旨在比较不同系统的单采程序的可行性和有效性。我们中心使用了两种单采系统[Com.Tec（费森尤斯医疗）和Spectra Optia（卡瑞迪安BCT）]来采集用于自体和异体移植的PBSC。我们回顾性分析了2012年6月至2014年11月在多库兹艾吕尔大学血液科对健康供者和患者进行的190次单采程序。PBSC通过费森尤斯细胞分离器采集（64次程序）或Spectra Optia细胞分离器采集（126次程序）。动员治疗方案为粒细胞集落刺激因子（G-CSF，26.8%）、环磷酰胺加G-CSF（48.4%）、普乐沙福加G-CSF（14.7%）、依托泊苷、甲泼尼龙、阿糖胞苷和顺铂（ESHAP，10%）以及其他方案。费森尤斯和Spectra Optia单采组的患者和供者特征（年龄、体重、处理的血量、疾病、动员方案）相似。尽管两者都能有效地采集PBSC，但Spectra Optia设备采集的产品中CD34+细胞数量显著更高（P<0.05），且产品体积显著低于费森尤斯Com.Tec（P<0.05）。就所有程序而言，Spectra Optia的“CD34+采集效率”显著高于费森尤斯Com.Tec（CE2：87%，70%，P=0.033）。高采集效率和低产品体积可能是Spectra Optia设备的一个显著特征（平均187 mL，产品CD34+细胞：1576 μL）。
